In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
Yahoo! Finance
New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
PR Newswire
New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
PharmiWeb
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Healthcare Industry Baden Württemberg (powered by BioPro)
BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON). The main objective of…
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Yahoo! Finance
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.